Corinna Panlilio Sison, MD

Director, Clinical Strategy https://www.hematologyadvisor.com

Corinna Panlilio Sison, MD, is the director of clinical strategy for the Haymarket Medical Network, part of the Medical Communications Group of Haymarket Media. She received her BA in biology from the University of Pennsylvania and her MD from the University of Medicine and Dentistry of New Jersey.

All articles by Corinna Panlilio Sison, MD

Investigators demonstrated that the risk of histologic transformation appeared lower than for follic

Lymphoma

Updated RA Biologics Registry Data for TNFi Lymphoma Risk

Corinna Panlilio Sison, MD

August 16, 2016

New data analyzed including over 120 000 patient years of tumor necrosis factor inhibitor (TNFi) or conventional synthetic disease-modifying antirheumatic drug (csDMARD) exposure did not find an increased risk of lymphoma in the 8 year followup period after TNFi initiation.

Next post in Lymphoma

Corinna Panlilio Sison, MD

All articles by Corinna Panlilio Sison, MD

Updated RA Biologics Registry Data for TNFi Lymphoma Risk

Odronextamab Granted Priority Review for R/R Follicular Lymphoma, DLBCL